自醫院住院與實習醫師中徵求篩選三十名符合健康人標準的志願者，編列為實驗組與對照組各十五名。實驗組口服生脈散，對照組口服安慰劑。以KENLU model.K-300 水銀式血壓計、TOSHIBA SSA-270A 型心臟超音波與同步心電圖儀進行測量。記錄志願受試者在服藥前與服藥後兩小時內的血壓、心率與左心室功能的變化情況。結果發現：口服生脈散後，人體平均動脈壓降低、周邊阻力降低、心肌纖維短縮分率與左心室搏出分率增加。顯示口服生脈散對正常人可能有擴張血管，降低後負荷，同時增加左心室功能的作用。Thirty volunteers matching the criteria of “Healthy” were recruited from the staff of China Medical College Hospital. Sheng-Mai-San was prescribed for the study group and Placebo to the control group. Effect of Sheng-Mai-San on human blood pressure, heart rate and left ventricular performance was evaluated before and after the administration of these agents. A Kenlu-model K-300 Sphygmomanometer, TOSHIBA SSA-270A echocardiography (M-mode) and electrocardiography were arranged for the detection and record of cardiovascular parameters. After taking Sheng-Mai-San, the study group showed reduction of the blood pressure and the peripheral resistance, in the meanwhile increase of the fractional shortening and the ejection fraction was noted. The result suggest that Sheng-Mai-San may be a potential cardiovascular activator to the the healthy, and it can promote the left ventricular performance by vasodilatation.